THELMA Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
THELMA Therapeutics has a total shareholder equity of ₩22.9B and total debt of ₩2.5B, which brings its debt-to-equity ratio to 10.7%. Its total assets and total liabilities are ₩27.2B and ₩4.4B respectively.
Key information
10.7%
Debt to equity ratio
₩2.46b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩8.69b |
| Equity | ₩22.87b |
| Total liabilities | ₩4.37b |
| Total assets | ₩27.24b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: A015540's short term assets (₩25.3B) exceed its short term liabilities (₩4.2B).
Long Term Liabilities: A015540's short term assets (₩25.3B) exceed its long term liabilities (₩149.6M).
Debt to Equity History and Analysis
Debt Level: A015540 has more cash than its total debt.
Reducing Debt: A015540's debt to equity ratio has reduced from 67.5% to 10.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A015540 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A015540 has sufficient cash runway for 1 years if free cash flow continues to grow at historical rates of 1.6% each year.